12.2 Medicine Registration, Pricing & Supply Chain

Why Registration Comes Before Marketing

A fundamental principle of UAE pharmaceutical law — tested repeatedly on the DHA exam — is that no medical product may be manufactured, imported, marketed, sold or dispensed in the UAE unless it is registered with the federal regulator (historically MOHAP, now the Emirates Drug Establishment (EDE)). Registration requires a comprehensive product dossier demonstrating:

• Quality — full pharmaceutical and analytical data on the drug substance and finished product, stability studies appropriate to the Gulf climate zone, and manufacturing details.
• Safety and efficacy — preclinical and clinical evidence supporting the claimed indications.
• Good Manufacturing Practice (GMP) — the manufacturing site must hold acceptable GMP certification from a recognised authority; site inspection may follow.

If a physician prescribes a medicine that is not registered in the UAE, the pharmacist cannot simply dispense an imported version from personal or informal stock; supply must go through authorised channels (for example, a licensed importer obtaining a special permit for an unregistered product for a named patient). Dispensing unregistered stock through the normal supply chain is a violation.

Marketing authorisation holder and local agent

The marketing authorisation holder (MAH) — often the foreign manufacturer — does not usually deal with the UAE market directly. Federal practice requires an appointed local agent: a UAE-licensed pharmaceutical establishment (typically a pharmaceutical warehouse/store or scientific office) that holds the product agency, liaises with the regulator, manages importation, handles batch recall and pharmacovigilance reporting, and is answerable for the product locally. A product without a licensed local agent effectively cannot be legally distributed.

Official Pricing Controls

Medicine prices in the UAE are not set by the free market. The federal regulator approves an official selling price at registration (and can revise it, including the well-publicised price-reduction rounds of the past decade). Practical consequences for the pharmacist:

• Community pharmacies must sell at the approved retail price; charging more is a violation, and the price is often printed on or verifiable for the pack.
• Discounting schemes and promotions on prescription medicines are restricted; the exam expects you to know pricing is regulated even if exact mechanisms are not.

Importation and the Distribution Hierarchy

The lawful supply chain is a strict hierarchy:

Manufacturer → licensed pharmaceutical warehouse/store (the local agent/importer) → licensed pharmacy → patient.

Key importation rules:

1. Only licensed importers — pharmaceutical warehouses holding the relevant establishment licence and product agency may import medicines. A community pharmacy cannot import commercial stock directly from abroad.
2. Import permits — each consignment requires an import permit issued against the product's registration, with customs clearance tied to it.
3. Cold chain — temperature-sensitive products (insulins, vaccines, many biologics) must be shipped, stored and distributed within the labelled range, classically 2–8 °C for refrigerated items, with calibrated monitoring and documented temperature logs at every step. A break in the cold chain is a quality defect, not a paperwork issue.
4. Narcotic and psychotropic imports are a distinct, stricter category: they require specific permits for controlled substances in defined quantities, over and above the ordinary import permit, and are reconciled against controlled-drug registers.

Parallel and personal import restrictions

Parallel importation (bringing in a registered medicine through an unauthorised channel to arbitrage price) is not permitted as a commercial practice. Personal importation by travellers is tolerated only in narrow circumstances — small quantities of non-controlled medicines for personal use, typically with the original prescription or doctor's letter, and some products are prohibited entirely. Controlled substances carried by travellers are heavily restricted. Exact permitted quantities are set by current customs and MOHAP/EDE guidance — candidates should check the current circulars rather than memorise day-limits.

Counterfeit Medicines and Tatmeen

The UAE is a high-volume re-export hub, which raises counterfeit/falsified medicine risk. The national countermeasure is Tatmeen, the UAE's track-and-trace platform:

• Every pack carries a GS1 DataMatrix barcode encoding a unique serial number, product code (GTIN), batch and expiry.
• Packs are scanned at defined points through the supply chain, allowing verification of authenticity and enabling targeted recalls.
• Pharmacists should treat missing, duplicated or unreadable serialisation data as a red flag and quarantine suspect stock.

Dealing in falsified medicines is among the most serious offences under the federal law.

Good Distribution Practice and Promotion Controls

Good Distribution Practice (GDP) obligations run alongside GMP: licensed warehouses must maintain qualified premises, temperature mapping and monitoring, segregation of controlled and recalled stock, pest control, and documented receipt/dispatch records. Finally, promotion and samples are controlled: marketing of prescription-only medicines is directed at healthcare professionals through licensed scientific offices, free medical samples must pass through licensed channels and must never be sold, and advertising medicines directly to the public is restricted — especially for prescription products.

Recalls and market surveillance

The supply chain also runs in reverse. When a quality defect, safety signal or falsified product is identified, the federal regulator can order a batch recall or market withdrawal, executed by the local agent through the licensed warehouses down to pharmacy level. Pharmacists must act on recall notices promptly: identify and quarantine affected batch numbers, stop dispensing, and return stock through authorised channels rather than selling it down. Related duties include participating in pharmacovigilance — a pharmacist who encounters a serious suspected adverse drug reaction or a product quality complaint is expected to report it through the established national reporting channels rather than ignore it. The Tatmeen serialisation data makes targeted recalls feasible, because affected packs can be traced to the sites that scanned them.